All News
Xeljanz Cancer Risks Detailed
MedPage Today
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
Read Article
Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis
Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.
Read Article
A Multidimensional Approach in the Management of Axial Spondylarthritis
Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis.
https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo
Links:
Dr. John Cush RheumNow ( View Tweet)
Visit our podcast channel and listen to experts from the #SLEEducatorsNetwork discuss how biologic therapies could help address key unmet needs in #lupus, and how clinicians can identify the most appropriate patients for biologics.
#SponsoredbyGSKUSMA
https://t.co/zYB48YvNDC https://t.co/gL67G5jQv8
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx in 35%. Findings: livedo racemosa (45%), necrosis/ulcers (42%), splinter hemorrhages (29%), distal edema (23%), purpura (14%). https://t.co/zFsPUdo4Wb https://t.co/rEN4yfoP9h
Links:
Dr. John Cush RheumNow ( View Tweet)
Sparks editorial -- RA pathogenesis has been linked to pollution, Lung Dz, smoking, silica dust, asbestos, textile dust, brick/concrete laying, pesticides, military burn pits - some w/ strong associ w/ HLA-SE and ACPA, but not ACPA-negative RA https://t.co/ZStmF8MeLD https://t.co/xQxJ74aQ81
Links:
Dr. John Cush RheumNow ( View Tweet)
SLE: Variability in Racial Disparities in Pregnancy Outcomes
Significant disparities exist in pregnancy outcomes in women with SLE, w/previous cohorts identifying Black women as having a higher risk of maternal mortality compared to White women w/SLE.
https://t.co/1PrJYpMcHx https://t.co/YN7K0Gf5Jl
Links:
Dr. John Cush RheumNow ( View Tweet)
Tapering Methotrexate with Biologics or JAK Inhibitors in RA
Dr Segan ( @JulianSegan) discusses Abstract 0916 at #ACR22.
https://t.co/CUjZ7SiSoE https://t.co/VYtmCIJEt6
Links:
Dr. John Cush RheumNow ( View Tweet)
Lifestyle Modifications may enhance TNF Inhibitors in axSpA
https://t.co/0O4jd3g0WL https://t.co/zUaRUR9tGL
Links:
Dr. John Cush RheumNow ( View Tweet)
The Top 10 Research Priorities in Psoriatic Arthritis
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
https://t.co/zfivHvtLX9 https://t.co/LZsiE417w2
Links:
Dr. John Cush RheumNow ( View Tweet)
Multi-ancestry analysis reveals novel genetic loci associated with OA
https://t.co/AIo3il8uHP https://t.co/nXGtOCCZsA
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic review comparing MIS-C and Kawasaki: 14 studies, 2928 pts; major differences- KD pts were younger; MIS-C had more Pulm, GI, Shock, more cardiac (LV, valvular pericarditis, myocarditis), but less coronary lesions & conjunctivitis https://t.co/bcCRh5HxL7 https://t.co/qLvfCYwx9u
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparing Biosimilar Growth in the US, Germany, and Switzerland
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
https://t.co/LYcG0BNO6C https://t.co/V2m8HoIWLF
Links:
Dr. John Cush RheumNow ( View Tweet)
GCA: What we feel and what we can't
Dr. David Liew ( @drdavidliew) discusses Abstracts 0483 and 0486 at #ACR22 Convergence.
https://t.co/Pobsb2anLa https://t.co/RQS4N3TqgK
Links:
Dr. John Cush RheumNow ( View Tweet)
Timely Fetal Screening Important in Positive Anti-Ro Antibody Pregnancies
Dr. Yusof ( @Yuz6Yusof) discusses Abstract 0957 presented at #ACR22.
https://t.co/yl4K7jZMGr https://t.co/6733AEhRyX
Links:
Dr. John Cush RheumNow ( View Tweet)
Imaging in PMR
One of the major limitations of PMR management is the lack of a gold standard investigation or biomarker of disease activity.
https://t.co/sZtgWKAtFv https://t.co/4H4tAY6CIZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Why treatment of pre-RA isn't ready for prime time
The ACR Great Debate was on "To treat or not to treat in pre-RA?" and it was stressed that autoimmunity may start well before clinical symptoms occur.
https://t.co/A0dx3PFyiJ https://t.co/wqBuM8XD7M
Links:
Dr. John Cush RheumNow ( View Tweet)
Familial Mediterranean Fever mimics
Dr Baspinar et al. performed a large case-control study in Turkey to assess whether acute abdomen episodes which led to appendectomies could be misdiagnosed as appendicitis rather than FMF-associated serositis.#ACR22
https… https://t.co/fHgeoLjNOu
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine: Cumulative Doses and Thresholds
Dr. Sheila Reyes ( @RHEUMarampa) discusses Abstracts 0982 and 0344 at #ACR22 Convergence.
https://t.co/k33LUNnTmV https://t.co/AJSBdT4rJC
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler ( @lianegensler discusses the following abstracts presented at #ACR22. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
https://t.co/0wCxKyFM0u https://t.co/8vaZ1ZncjF
Links:
Dr. John Cush RheumNow ( View Tweet)
